The global glycated albumin assay market is projected to reach USD 0.3 billion by 2028 from USD 0.2 billion in 2023, at a CAGR of 8.9%
Glycated Albumin Assay Market in terms of revenue was estimated to be worth $0.2 billion in 2023 and is poised to reach $0.3 billion by 2028, growing at a CAGR of 8.9% from 2023 to 2028 according to a new report by MarketsandMarkets™. Government assistance is stimulating the market. Players in the glycated albumin assay market have significant potential in developing nations like India and Japan. Additionally, the aging population in developed and developing nations would favorably impact the market for glycated albumin assay. The prevalence of age-related illnesses like diabetes and pancreatic disorders is anticipated to rise dramatically as the senior population is forecast to grow quickly. Numerous test prescriptions to assess the levels of creatinine, albumin, glucose, ketones, and bilirubin are caused by diagnosing and treating such disorders, which is driving the market’s expansion. Browse through 100 market data tables and 44 figures spread across 180 pages and the in-depth TOC of the glycated albumin assay market.
Download an Illustrative overview: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=265553363
Based on application, the glycated albumin assay market is segmented into prediabetes, type 1 diabetes, and type 2 diabetes. The type 2 diabetes segment accounted for the largest share of the glycated albumin assay market, mainly due to increased focus on type 2 diabetes care and increased funding for diagnostic research.
The significant market share of this sector is mostly due to an increased emphasis on early disease diagnosis. Additionally, hospitals and diabetes care facilities are committed to providing patients with diabetes-specialized care. Their focus on comprehensive diabetes care makes them primary locations for conducting glycated albumin assays, which are important diagnostic tests for monitoring glycemic control.
North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa are the five main geographic segments of the worldwide glycated albumin assay market. In 2022, the glycated albumin assay market’s largest regional market was North America. The government’s support for regional research and increased funding for the creation of preventive care diagnostics can be used to explain North America’s significant market dominance.
Glycated Albumin Assay Market Dynamics:
Drivers:
Restraints:
Opportunities:
Challenges:
Key Market Players:
The major players operating in this market are Asahi Kasei Corporation (Japan), Beijing Strong Biotechnologies, Inc. (China), Diazyme Laboratories, Inc. (US), DxGen Corp. (South Korea), Weldon Biotech (India), Hzymes Biotech (China).
In 2022, Asahi Kasei Corporation (Japan) led the glycated albumin assay market. The company has maintained a leading position in the market through its strong presence worldwide. The company partners with third parties to offer integrated solutions. The company’s strategy focuses on four factors: affordability, capacity, outcome certainty, and values. The firm implements tailored pricing solutions to ensure maximum patient access. The company also focuses on developing new pricing models for its customers. Additionally, Asahei strategically invests in R&D to strengthen its position in the market. For instance, the company’s R&D expenditure accounted for USD 5.1 billion in 2022. This rise in R&D spending indicates the company’s growing focus on innovation and diversification in emerging markets.
In 2022, Beijing Strong Biotechnologies, Inc. (China) was the second-largest market player in the glycated albumin assay ecosystem. It has an increased presence in Asia Pacific with a strong network and growth strategies and has a product portfolio in the glycated albumin assay market. The company focuses on increasing R&D with increased investment in innovation.
Hymes Biotech, a prominent player in the global glycated albumin assay market, secured a significant market share in the glycated albumin assay market in 2022. The company’s strong presence in China serves as a foundation for expanding its operations in emerging markets like Asia Pacific, thereby strengthening its geographical reach. The company focuses on research and development as well as expanding the manufacturing of the glycated albumin assay market. These strategic initiatives enable Hymes to secure a larger market share and strengthen its position in the glycated albumin assay market.
© 2024 Crivva. All Rights Reserved.